Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Santen, RIKEN, FBRI Sign Drug Discovery Deal for Retinal Disease
October 7, 2016
- Teikoku Seiyaku, Mitsubishi Tanabe Hook Up on Sales of Anti-Allergy Agents
October 6, 2016
- GHIT Fund to Invest 1.1 Billion Yen in Development of Neglected Disease Drugs
October 6, 2016
- Eurofarma Gets Latin American Rights to Eisai’s Cancer Candidate Farletuzumab
October 5, 2016
- Daiichi Sankyo, AgonOx Ink Immuno-Oncology Research Collaboration
October 5, 2016
- Marc van der Heijden to Lead Allergan Japan
October 4, 2016
- Daiichi Sankyo Launches Large-Scale Research in Elderly NVAF Patients
October 4, 2016
- Constipation Drug Delivers Positive PIII Data in Japan: EA Pharma, Mochida
October 4, 2016
- Mitsubishi Tanabe Looks to Double Late-Stage Pipelines; Faster Decisions Hold Key in Curbing Costs
October 3, 2016
- Data Out to Support Long-Term Use of Entyvio: Takeda
October 3, 2016
- Eisai to Kick Off Global PIII for Lenvatinib as First-Line RCC Therapy
October 3, 2016
- Mochida to Solely Distribute Janssen’s Pain Drug Tramcet from January
October 3, 2016
- Teva Pharma Japan Renamed “Teva Takeda Pharma”
October 3, 2016
- Takecab Most Heavily Promoted Drug in August: Anterio
October 3, 2016
- Suzuken’s Harvoni Sales Sag 70% from Peak, Wholesaler Earnings Certain to Take Hit
September 30, 2016
- Daiichi Sankyo, Zymeworks Seal Immuno-Oncology Cross-Licensing Pact
September 30, 2016
- Chugai Licenses Atopic Dermatitis Hopeful to Maruho in Japan, Retains Rights for Hemodialysis Pruritus
September 29, 2016
- Maruho Gets Rights to Astellas’ JAK Inhibitor for Skin Diseases
September 29, 2016
- Pruritus Drug Remitch Filed for Use in Peritoneal Dialysis Patients
September 29, 2016
- Tokyo Startup’s Osteoarthritis Drug Hopeful on Tap for PIb Launch by Year-End
September 28, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…